Eyevensys uses its EyeCET platform to enable sustained intraocular production of therapeutic proteins to treat a range of ophthalmic diseases, including chronic non-infectious uveitis, degenerative retinal diseases, retinal vascular diseases, and macular edema. Their technology improves short and long-term therapeutic outcomes, enhances patient compliance, and significantly improves the tolerability of treatment. The lead product, EYS606, has been granted an Orphan designation by the EMA for the treatment of NIU and has received regulatory clearance to begin a Phase I/II clinical trial in France and the UK.